Analisi facoltativa del prodotto
Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Regeneron Pharmaceuticals Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $74.9B | |
|---|---|---|
| P/E (forward) | 13.3x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | — | $12.17B | $13.12B | $14.20B | $14.34B | +5.6% |
| Gross profit | — | $10.61B | $11.30B | $12.23B | $12.24B | +4.9% |
| Operating income | — | $4.92B | $4.27B | $4.84B | $5.27B | +2.4% |
| Net income | — | $4.34B | $3.95B | $4.41B | $4.50B | +1.3% |
| EPS (diluted) | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | -12.9% |
| EBITDA | — | $5.26B | $4.69B | $5.32B | $5.82B | +3.4% |
| R&D | — | $3.85B | $4.63B | $5.23B | $5.85B | +15.0% |
| SG&A | — | $2.12B | $2.63B | $2.95B | $2.70B | +8.5% |
Recent company headlines from major financial publishers.
Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.
Our baseline assumes a successful transition from legacy assets to next-gen indications. Margins normalize to 30% as peak R&D spending subsides, anchoring fair value at $1,210 and bridging the gap from overly pessimistic internal valuation cross-checks.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 5.6% | $1,545 | $1,793 | $2,117 | $2,117 | $2,117 |
| 6.6% | $1,210 | $1,357 | $1,545 | $1,793 | $2,117 |
| 7.6% | $994 | $1,091 | $1,210 | $1,357 | $1,545 |
| 8.6% | $844 | $913 | $994 | $1,091 | $1,210 |
| 9.6% | $733 | $784 | $844 | $913 | $994 |
Upcoming earnings date and setup when available.
Il rating riportato dall'edizione di ricerca pubblicata ogni mese. Un rating confronta il prezzo alla data dell'analisi con il valore equo; non indica se la valutazione si è rivelata corretta.
| Anno | gen | feb | mar | apr | mag | giu | lug | ago | set | ott | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
